Patents Assigned to Salix Pharmaceuticals, Inc.
-
Patent number: 9273066Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.Type: GrantFiled: October 24, 2013Date of Patent: March 1, 2016Assignee: Salix Pharmaceuticals, Inc.Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Patent number: 9273063Abstract: A process is described which enables Rifaximin in a completely amorphous form to be obtained. Said process comprises the steps of dissolving crude Rifaximin in absolute ethanol while hot and then collecting after precipitation by—cooling the title compound under amorphous form.Type: GrantFiled: April 24, 2014Date of Patent: March 1, 2016Assignee: Salix Pharmaceuticals, Inc.Inventors: Emilio Vecchio, Roberta Pizzocaro
-
Patent number: 9192616Abstract: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.Type: GrantFiled: April 4, 2012Date of Patent: November 24, 2015Assignee: Salix Pharmaceuticals, Inc.Inventor: Lorin Johnson
-
Patent number: 9035046Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.Type: GrantFiled: June 30, 2014Date of Patent: May 19, 2015Assignees: Salix Pharmaceuticals, Inc., Alfa Wassermann, S.P.A.Inventors: Pam Golden, Mohammed A. Kabir, Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Miriam Barbanti
-
Patent number: 9034892Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.Type: GrantFiled: June 27, 2013Date of Patent: May 19, 2015Assignee: Salix Pharmaceuticals, Inc.Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Patent number: 8921344Abstract: A method of increasing the bioavailability of 5-aminosalicylate compound by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of 5-aminosalicylate compound in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.Type: GrantFiled: November 3, 2006Date of Patent: December 30, 2014Assignee: Salix Pharmaceuticals, Inc.Inventor: Lorin Johnson
-
Publication number: 20140349982Abstract: Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis.Type: ApplicationFiled: May 20, 2014Publication date: November 27, 2014Applicant: Salix Pharmaceuticals, Inc.Inventors: William Forbes, Enoch Bortey, Craig Paterson, Pam Golden
-
Patent number: 8507009Abstract: This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.Type: GrantFiled: January 20, 2010Date of Patent: August 13, 2013Assignee: Salix Pharmaceuticals, Inc.Inventors: Stephen Skiendzielewski, Martin Rose, Ngoc Do
-
Publication number: 20130065862Abstract: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.Type: ApplicationFiled: April 4, 2012Publication date: March 14, 2013Applicant: Salix Pharmaceuticals, Inc.Inventor: Lorin Johnson
-
Publication number: 20090252788Abstract: The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.Type: ApplicationFiled: February 22, 2008Publication date: October 8, 2009Applicant: Salix Pharmaceuticals, Inc.Inventors: Joseph Lockhart, Brock Swanson, Lorin Johnson
-
Publication number: 20080306029Abstract: The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment of, for example, gastrointestinal malignancies, including colorectal, appendiceal, anal, or small bowel cancers; urogenital malignancies, including prostate, ladder, testicular, or penile cancers; gynecologic malignancies, including cervical, endometrial, ovarian, vaginal, or vulvar cancers; or osteogenic and other sarcomatous malignancies in which pelvic structures are involved, comprising the administration of a therapeutically effective amount of balsalazide to a patient in need thereof.Type: ApplicationFiled: May 27, 2005Publication date: December 11, 2008Applicant: Salix Pharmaceuticals, Inc.Inventors: Doug Bettenhausen, Christopher Jahraus
-
Patent number: 7452872Abstract: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.Type: GrantFiled: August 8, 2007Date of Patent: November 18, 2008Assignee: Salix Pharmaceuticals, Inc.Inventor: Lorin Johnson
-
Publication number: 20080260682Abstract: This invention relates to novel colonic purgative compositions of polyethylene glycol having an average molecular weight of at least 1,000 or at least 4,000. Further, this invention relates to methods of using the colonic purgative compositions. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.Type: ApplicationFiled: November 2, 2007Publication date: October 23, 2008Applicant: Salix Pharmaceuticals, Inc.Inventors: Martin Rose, Robert Apple, Stephen Skiendzielewski
-
Publication number: 20080213393Abstract: This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.Type: ApplicationFiled: March 13, 2008Publication date: September 4, 2008Applicant: Salix Pharmaceuticals, Inc.Inventors: Stephen Skiendzielewski, Martin Rose, Ngoc Do
-
Publication number: 20080096849Abstract: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.Type: ApplicationFiled: October 23, 2007Publication date: April 24, 2008Applicant: Salix Pharmaceuticals, Inc.Inventor: Lorin Johnson
-
Publication number: 20070265232Abstract: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.Type: ApplicationFiled: August 8, 2007Publication date: November 15, 2007Applicant: SALIX PHARMACEUTICALS, INC.Inventor: Lorin Johnson
-
Patent number: 5905073Abstract: The present invention provides a method of colon cancer chemoprevention or chemotherapy comprising administering to an individual suffering from colon cancer or at risk to develop colon cancer a pharmaceutical composition comprising an effective amount of a 2-hydroxy-5-phenylazobenzoic acid derivative or an ester of an active metabolite or an oxidation product of an active metabolite thereof, or a pharmacologically acceptable salt of the 2-hydroxy-5-phenylazobenzoic acid derivative or an ester or an active metabolite or an oxidation product of an active matabolite thereof.Type: GrantFiled: July 11, 1996Date of Patent: May 18, 1999Assignee: Salix Pharmaceuticals, Inc.Inventors: Lorin K. Johnson, Marvin H. Sleisenger